AL
SPE

Aspiriant LLC’s Special Opportunities Fund SPE Stock Holding History

Aspiriant LLC’s Portfolio SPE Stock Details SPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,866
Closed -$194K – 301
2024
Q4 		$194K Buy
+13,866
New +$195K 0.01% 284

Other funds holding SPE

Kovitz Investment Group Partners
Kovitz Investment Group Partners Chicago, Illinois $4.31B AUM 20.41% 1-Year Est. Return
BBPWM
Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
SFS
Shaker Financial Services Arlington, Virginia $319M AUM 3.9% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Aspiriant LLC's SPE Position: Q1 2025 in Review

Aspiriant LLC sold out of Special Opportunities Fund (SPE) in Q1 2025, closing a stake of 13,866 shares — an estimated $194K sold.

Aspiriant LLC first reported a position in SPE in Q4 2024 and held it in 1 quarter. The position peaked at $194K in Q4 2024. 37 funds tracked by Wall St. Rank hold SPE as of Q1 2025.

  • Aspiriant LLC reported no remaining Special Opportunities Fund position as of Q1 2025 after selling out during the quarter.
  • Aspiriant LLC sold 13,866 Special Opportunities Fund shares in Q1 2025, an estimated $194K.
  • Aspiriant LLC first reported a position in Special Opportunities Fund in Q4 2024 and held it in 1 quarter.
  • Aspiriant LLC's Special Opportunities Fund position peaked at $194K in Q4 2024.
  • 37 funds tracked by Wall St. Rank held Special Opportunities Fund as of Q1 2025.

Based on Aspiriant LLC's 13F filing for Q1 2025, filed 21 Apr 2025.